Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross‐over study
The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tab...
Saved in:
| Published in | Clinical and translational science Vol. 14; no. 6; pp. 2408 - 2419 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.11.2021
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration (Tmax) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time‐curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin‐to‐no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin‐to‐no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug‐drug interaction between metformin and codeine seems plausible. |
|---|---|
| AbstractList | The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as
CYP2D6
normal metabolizers (
*1/*1
) without known reduced function variants in the
OCT1
gene (
rs12208357
,
rs34130495
,
rs34059508
, and
rs72552763
) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration (
T
max
) after oral intake of metformin was 2 h without, and 3 h with codeine (
p
= 0.06). The geometric mean ratios of the areas under the plasma concentration time‐curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin‐to‐no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin‐to‐no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug‐drug interaction between metformin and codeine seems plausible. The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration (Tmax) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time‐curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin‐to‐no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin‐to‐no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug‐drug interaction between metformin and codeine seems plausible. The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers ( *1/*1 ) without known reduced function variants in the OCT1 gene ( rs12208357 , rs34130495 , rs34059508 , and rs72552763 ) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration ( ) after oral intake of metformin was 2 h without, and 3 h with codeine ( p = 0.06). The geometric mean ratios of the areas under the plasma concentration time‐curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin‐to‐no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin‐to‐no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug‐drug interaction between metformin and codeine seems plausible. Abstract The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration (Tmax) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time‐curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin‐to‐no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin‐to‐no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug‐drug interaction between metformin and codeine seems plausible. The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration ( ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time-curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin-to-no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin-to-no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug-drug interaction between metformin and codeine seems plausible. The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time-curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin-to-no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin-to-no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug-drug interaction between metformin and codeine seems plausible.The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration ( T max ) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time-curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin-to-no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin-to-no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug-drug interaction between metformin and codeine seems plausible. The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive on four separate occasions: (A) orally administered metformin (1 g), (B) intravenously administered metformin (0.5 g), (C) five doses of tablet codeine 25 mg; the last dose was administered together with oral metformin (1 g), and (D) five doses of tablet codeine 25 mg; the last dose was administered together with metformin (0.5 g) intravenously. Blood samples were drawn for 24 h after administration of metformin, and for 6 h after administration of codeine and analyzed using liquid chromatography and tandem mass spectrometry. Healthy volunteers genotyped as CYP2D6 normal metabolizers (*1/*1) without known reduced function variants in the OCT1 gene (rs12208357, rs34130495, rs34059508, and rs72552763) were invited. The median absorption fraction of metformin was 0.31 and was not influenced by codeine intake. The median time to maximum concentration (Tmax) after oral intake of metformin was 2 h without, and 3 h with codeine (p = 0.06). The geometric mean ratios of the areas under the plasma concentration time‐curve (AUCs) for morphine and its metabolites M3G and M6G for oral intake of metformin‐to‐no metformin were 1.21, 1.31, and 1.27, respectively, and for i.v. metformin‐to‐no metformin 1.28, 1.34, and 1.30, respectively. Concomitant oral and i.v. metformin increased the plasma levels of morphine, M3G and M6G. These small pharmacokinetic changes may well contribute to an increased risk of early discontinuation of metformin. Hence, a clinically relevant drug‐drug interaction between metformin and codeine seems plausible. |
| Author | Nøddebo Nyrup, Amanda Damkier, Per Bjerregaard Stage, Tore Brøsen, Kim Korshøj Bergmann, Troels Nielsen, Flemming Kuhlmann, Ida Hougaard Christensen, Mette Marie Højlund, Kurt |
| AuthorAffiliation | 1 Department of Public Health, Clinical Pharmacology Pharmacy and Environmental Medicine University of Southern Denmark Odense Denmark 2 Department of Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark 3 Department of Clinical Research University of Southern Denmark Odense Denmark 4 Department of Regional Health Research University of Southern Denmark Esbjerg Denmark 5 Steno Diabetes Center Odense Odense University Hospital Odense Denmark 6 OPEN Odense Patient data Explorative Network Odense University Hospital Odense Denmark |
| AuthorAffiliation_xml | – name: 4 Department of Regional Health Research University of Southern Denmark Esbjerg Denmark – name: 1 Department of Public Health, Clinical Pharmacology Pharmacy and Environmental Medicine University of Southern Denmark Odense Denmark – name: 2 Department of Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark – name: 5 Steno Diabetes Center Odense Odense University Hospital Odense Denmark – name: 3 Department of Clinical Research University of Southern Denmark Odense Denmark – name: 6 OPEN Odense Patient data Explorative Network Odense University Hospital Odense Denmark |
| Author_xml | – sequence: 1 givenname: Ida surname: Kuhlmann fullname: Kuhlmann, Ida email: ikuhlmann@health.sdu.dk organization: University of Southern Denmark – sequence: 2 givenname: Amanda surname: Nøddebo Nyrup fullname: Nøddebo Nyrup, Amanda organization: University of Southern Denmark – sequence: 3 givenname: Tore surname: Bjerregaard Stage fullname: Bjerregaard Stage, Tore organization: University of Southern Denmark – sequence: 4 givenname: Mette Marie surname: Hougaard Christensen fullname: Hougaard Christensen, Mette Marie organization: University of Southern Denmark – sequence: 5 givenname: Troels surname: Korshøj Bergmann fullname: Korshøj Bergmann, Troels organization: University of Southern Denmark – sequence: 6 givenname: Per surname: Damkier fullname: Damkier, Per organization: University of Southern Denmark – sequence: 7 givenname: Flemming surname: Nielsen fullname: Nielsen, Flemming organization: University of Southern Denmark – sequence: 8 givenname: Kurt surname: Højlund fullname: Højlund, Kurt organization: Odense University Hospital – sequence: 9 givenname: Kim surname: Brøsen fullname: Brøsen, Kim organization: Odense University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34268884$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAQgCNURH_gwAsgS1zgsK2d2I7NAala8VOpUg-UszVxnMbbJF5sZ6u9wRvwjDwJTrasaCXwxdb4m08zHh9nB4MbTJa9JPiUpHWmYzglBcHlk-yIlCxfCMzzg_2Z0cPsOIQVxrzggj3LDguacyEEPcp-XHnoEAw1skP0sDGDGwNat-B70O7WDiZaHZBrUG9i43xvB3RnYzunTAc3RuQmh3a1SfjkgdtpQ62BLrZbFMZqZVKN79A50t6F8Ov7T7cxHoU41tvn2dMGumBe3O8n2dePH66XnxeXV58ulueXC82wLBcECGMlg7phBGrZEEaklg2UZSFFU0kwLBfcSFKIsqRFhYHmQmNR8EYCT5GT7GLnrR2s1NrbHvxWObBqDjh_o8CnZjujKoq14WUOteaUA0l-I2lBieCaAW-S6_3OtR6r3tTaTG_XPZA-vBlsq27cRgmOaU5lEry5F3j3bTQhqt4GbboOBpMGoHLGcimpnNHXj9CVG_2QnipRUmIpczx19-rvival_Jl0At7ugHkC3jR7hGA1_SKVJqTmX5TYs0esthGidVMztvtfxp3tzPbfarW8_rLL-A0xV9s4 |
| CitedBy_id | crossref_primary_10_1111_bcpt_13667 crossref_primary_10_1007_s11095_024_03664_8 crossref_primary_10_1111_bcpt_13703 crossref_primary_10_1111_dom_15759 crossref_primary_10_1016_j_rico_2024_100404 |
| Cites_doi | 10.1038/clpt.1990.212 10.1007/s00125-015-3844-9 10.1007/s00125-017-4335-y 10.2337/db14-1388 10.2165/00003088-199324040-00007 10.1111/bcp.13049 10.1111/j.1365-2125.1981.tb01206.x 10.1002/cpt1978246683 10.1016/j.ejpb.2016.11.034 10.1111/dom.12812 10.1007/s11095-018-2526-y 10.1002/cpt.1098 10.2337/dc18-2182 10.1124/pr.118.015578 10.1038/s41598-019-42531-0 10.1111/nmo.13733 10.1111/j.1476-5381.1994.tb13128.x 10.1007/s002280050200 10.1016/j.jbi.2008.08.010 10.1124/jpet.102.034140 10.1016/j.xphs.2017.04.078 10.1111/bcpt.12579 10.1007/s00125-015-3733-2 10.1007/BF00562061 10.1111/j.1365-2125.1991.tb05550.x 10.1016/j.bcp.2013.06.019 10.1038/s41574-019-0242-2 10.2967/jnumed.116.177774 10.1152/ajpendo.00365.2002 10.1007/s00125-008-1053-5 10.1111/bcp.14591 10.1016/j.mito.2014.05.007 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics – notice: 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. – notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TK 7TM 7U9 7X7 7XB 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7N M7P P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 5PM DOA |
| DOI | 10.1111/cts.13107 |
| DatabaseName | Wiley_OA刊 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (ProQuest) ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Intravenous and oral metformin |
| EISSN | 1752-8062 |
| EndPage | 2419 |
| ExternalDocumentID | oai_doaj_org_article_b40ce672adc646a18fbe9434186c5a6f PMC8604249 34268884 10_1111_cts_13107 CTS13107 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Denmark |
| GeographicLocations_xml | – name: Denmark |
| GrantInformation_xml | – fundername: Danish Council for Independent Research funderid: 7016‐00052B – fundername: Danish Council for Independent Research grantid: 7016-00052B – fundername: ; grantid: 7016‐00052B |
| GroupedDBID | --- 05W 0R~ 10A 1OC 24P 29B 31~ 4.4 52S 53G 5GY 5VS 7X7 8-1 8FE 8FH 8FI 8FJ AAHHS AANHP AAZKR ABDBF ABUWG ACBWZ ACCFJ ACCMX ACRPL ACUHS ACXQS ACYXJ ADKYN ADNMO ADZMN ADZOD AEEZP AEQDE AFBPY AFKRA AFZJQ AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BBNVY BDRZF BENPR BHPHI BPHCQ BRXPI BVXVI CAG CCPQU COF CS3 DIK EBD EBS EJD EMOBN ESX F5P FEDTE FYUFA G-S GODZA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ IAO IHR ITC KQ8 LH4 LK8 LW6 M7P MY~ O9- OIG OK1 P2P PIMPY PQQKQ PROAC QB0 ROL RPM SUPJJ SV3 TUS UKHRP WIN XG1 AAYXX AGQPQ CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TK 7TM 7U9 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. M7N P64 PKEHL PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c5097-1a15575adf51ad9f1519c9fa77398fb9ae5286e91387743b0a428c0836f9a6743 |
| IEDL.DBID | 24P |
| ISSN | 1752-8054 1752-8062 |
| IngestDate | Wed Aug 27 01:32:23 EDT 2025 Thu Aug 21 18:36:28 EDT 2025 Thu Jul 10 21:58:23 EDT 2025 Wed Aug 13 04:36:58 EDT 2025 Wed Feb 19 02:27:20 EST 2025 Tue Jul 01 01:05:37 EDT 2025 Thu Apr 24 23:02:06 EDT 2025 Wed Jan 22 16:28:36 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5097-1a15575adf51ad9f1519c9fa77398fb9ae5286e91387743b0a428c0836f9a6743 |
| Notes | Funding information This study was supported by the Danish Council for Independent Research (grant number; 7016‐00052B), The Faculty of Medical Sciences, SDU and the Region of Southern Denmark. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.13107 |
| PMID | 34268884 |
| PQID | 2599099204 |
| PQPubID | 2029979 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b40ce672adc646a18fbe9434186c5a6f pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604249 proquest_miscellaneous_2552994949 proquest_journals_2599099204 pubmed_primary_34268884 crossref_primary_10_1111_cts_13107 crossref_citationtrail_10_1111_cts_13107 wiley_primary_10_1111_cts_13107_CTS13107 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | November 2021 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: November 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Clinical and translational science |
| PublicationTitleAlternate | Clin Transl Sci |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 1994; 112 1979; 16 1993; 24 2019; 9 2015; 58 2017; 60 2009; 42 1991; 31 2019; 15 2013; 86 2018; 104 1996; 51 2020; 32 2008; 51 2017; 112 2016; 59 2016; 57 2019; 42 1990; 48 2020; 72 2016; 118 2015; 64 2002; 302 2017; 19 2016; 82 2020; 87 1978; 24 2014; 17 2017; 106 1981; 12 2018; 35 2003; 284 e_1_2_11_10_1 e_1_2_11_32_1 e_1_2_11_31_1 e_1_2_11_30_1 e_1_2_11_14_1 e_1_2_11_13_1 e_1_2_11_12_1 e_1_2_11_34_1 e_1_2_11_11_1 e_1_2_11_33_1 e_1_2_11_7_1 e_1_2_11_29_1 e_1_2_11_6_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_2_1 e_1_2_11_21_1 e_1_2_11_20_1 e_1_2_11_25_1 e_1_2_11_24_1 e_1_2_11_9_1 e_1_2_11_23_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_18_1 e_1_2_11_17_1 e_1_2_11_16_1 e_1_2_11_15_1 e_1_2_11_19_1 |
| References_xml | – volume: 59 start-page: 426 issue: 3 year: 2016 end-page: 435 article-title: Metformin and the gastrointestinal tract publication-title: Diabetologia – volume: 302 start-page: 510 issue: 2 year: 2002 end-page: 515 article-title: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin publication-title: J Pharmacol Exp Ther – volume: 106 start-page: 2245 issue: 9 year: 2017 end-page: 2250 article-title: Transporters involved in metformin pharmacokinetics and treatment response publication-title: J Pharm Sci – volume: 9 start-page: 6156 issue: 1 year: 2019 article-title: Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport publication-title: Sci Rep – volume: 19 start-page: 290 issue: 2 year: 2017 end-page: 293 article-title: Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes publication-title: Diabetes Obes Metab – volume: 24 start-page: 344 issue: 4 year: 1993 end-page: 354 article-title: Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations publication-title: Clin Pharmacokinet – volume: 16 start-page: 195 issue: 3 year: 1979 end-page: 202 article-title: Pharmacokinetics of metformin after intravenous and oral administration to man publication-title: Eur J Clin Pharmacol – volume: 15 start-page: 569 issue: 10 year: 2019 end-page: 589 article-title: Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus publication-title: Nat Rev Endocrinol – volume: 112 start-page: 671 issue: 2 year: 1994 end-page: 675 article-title: Importance of the intestine as a site of metformin‐stimulated glucose utilization publication-title: Br J Pharmacol – volume: 48 start-page: 686 issue: 6 year: 1990 end-page: 693 article-title: Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine publication-title: Clin Pharmacol Ther – volume: 35 start-page: 243 issue: 12 year: 2018 article-title: Irinotecan alters the disposition of morphine via inhibition of organic cation transporter 1 (OCT1) and 2 (OCT2) publication-title: Pharm Res – volume: 82 start-page: 1002 issue: 4 year: 2016 end-page: 1010 article-title: Limited sampling strategy for determining metformin area under the plasma concentration‐time curve publication-title: Br J Clin Pharmacol – volume: 87 start-page: 1963 issue: 4 year: 2020 end-page: 1969 article-title: Using a limited sampling strategy (LSS) to investigate the interindividual pharmacokinetic variability in metformin ‐ a large prospective trial publication-title: Br J Clin Pharmacol – volume: 42 start-page: 1027 issue: 6 year: 2019 end-page: 1033 article-title: Variation in the plasma membrane monoamine transporter (PMAT) (Encoded by SLC29A4) and organic cation transporter 1 (OCT1) (Encoded by SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: An IMI DIRECT study publication-title: Diabetes Care – volume: 60 start-page: 1648 issue: 9 year: 2017 end-page: 1655 article-title: The pharmacogenetics of metformin publication-title: Diabetologia – volume: 112 start-page: 234 year: 2017 end-page: 248 article-title: Food, gastrointestinal pH, and models of oral drug absorption publication-title: Eur J Pharm Biopharm – volume: 51 start-page: 1552 issue: 8 year: 2008 end-page: 1553 article-title: Metformin and the intestine publication-title: Diabetologia – volume: 31 start-page: 381 issue: 4 year: 1991 end-page: 390 article-title: Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers publication-title: Br J Clin Pharmacol – volume: 51 start-page: 289 issue: 3–4 year: 1996 end-page: 295 article-title: Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects publication-title: Eur J Clin Pharmacol – volume: 284 start-page: E716 issue: 4 year: 2003 end-page: 725 article-title: Pathways for glucose disposal after meal ingestion in humans publication-title: Am J Physiol Endocrinol Metab – volume: 17 start-page: 76 year: 2014 end-page: 100 article-title: Comprehensive review on lactate metabolism in human health publication-title: Mitochondrion – volume: 57 start-page: 1920 issue: 12 year: 2016 end-page: 1926 article-title: In vivo imaging of human 11C‐metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses publication-title: J Nucl Med Off Publ Soc Nucl Med – volume: 12 start-page: 235 issue: 2 year: 1981 end-page: 246 article-title: Metformin kinetics in healthy subjects and in patients with diabetes mellitus publication-title: Br J Clin Pharmacol – volume: 104 start-page: 803 issue: 5 year: 2018 end-page: 817 article-title: Influence of transporter polymorphisms on drug disposition and response: A perspective from the international transporter consortium publication-title: Clin Pharmacol Ther – volume: 58 start-page: 2494 issue: 11 year: 2015 end-page: 2502 article-title: Endogenous glucose production increases in response to metformin treatment in the glycogen‐depleted state in humans: a randomised trial publication-title: Diabetologia – volume: 64 start-page: 1786 issue: 5 year: 2015 end-page: 1793 article-title: Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS study publication-title: Diabetes – volume: 42 start-page: 377 issue: 2 year: 2009 end-page: 381 article-title: Research electronic data capture (REDCap)–a metadata‐driven methodology and workflow process for providing translational research informatics support publication-title: J Biomed Inform – volume: 24 start-page: 683 issue: 6 year: 1978 end-page: 693 article-title: Disposition of metformin (N, N‐dimethylbiguanide) in man publication-title: Clin Pharmacol Ther – volume: 86 start-page: 666 issue: 5 year: 2013 end-page: 678 article-title: Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration publication-title: Biochem Pharmacol – volume: 72 start-page: 253 issue: 1 year: 2020 end-page: 319 article-title: Organic cation transporters in health and disease publication-title: Pharmacol Rev – volume: 32 issue: 1 year: 2020 article-title: Codeine delays gastric emptying through inhibition of gastric motility as assessed with a novel diagnostic intragastric balloon catheter publication-title: Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc – volume: 118 start-page: 487 issue: 6 year: 2016 end-page: 495 article-title: Early discontinuation of metformin in individuals treated with inhibitors of transporters of metformin publication-title: Basic Clin Pharmacol Toxicol – ident: e_1_2_11_12_1 doi: 10.1038/clpt.1990.212 – ident: e_1_2_11_19_1 – ident: e_1_2_11_31_1 doi: 10.1007/s00125-015-3844-9 – ident: e_1_2_11_2_1 doi: 10.1007/s00125-017-4335-y – ident: e_1_2_11_10_1 doi: 10.2337/db14-1388 – ident: e_1_2_11_26_1 doi: 10.2165/00003088-199324040-00007 – ident: e_1_2_11_18_1 doi: 10.1111/bcp.13049 – ident: e_1_2_11_21_1 doi: 10.1111/j.1365-2125.1981.tb01206.x – ident: e_1_2_11_22_1 doi: 10.1002/cpt1978246683 – ident: e_1_2_11_25_1 doi: 10.1016/j.ejpb.2016.11.034 – ident: e_1_2_11_30_1 doi: 10.1111/dom.12812 – ident: e_1_2_11_27_1 doi: 10.1007/s11095-018-2526-y – ident: e_1_2_11_16_1 doi: 10.1002/cpt.1098 – ident: e_1_2_11_11_1 doi: 10.2337/dc18-2182 – ident: e_1_2_11_6_1 doi: 10.1124/pr.118.015578 – ident: e_1_2_11_29_1 doi: 10.1038/s41598-019-42531-0 – ident: e_1_2_11_24_1 doi: 10.1111/nmo.13733 – ident: e_1_2_11_5_1 doi: 10.1111/j.1476-5381.1994.tb13128.x – ident: e_1_2_11_28_1 doi: 10.1007/s002280050200 – ident: e_1_2_11_17_1 doi: 10.1016/j.jbi.2008.08.010 – ident: e_1_2_11_7_1 doi: 10.1124/jpet.102.034140 – ident: e_1_2_11_8_1 doi: 10.1016/j.xphs.2017.04.078 – ident: e_1_2_11_9_1 doi: 10.1111/bcpt.12579 – ident: e_1_2_11_34_1 doi: 10.1007/s00125-015-3733-2 – ident: e_1_2_11_20_1 doi: 10.1007/BF00562061 – ident: e_1_2_11_13_1 doi: 10.1111/j.1365-2125.1991.tb05550.x – ident: e_1_2_11_14_1 doi: 10.1016/j.bcp.2013.06.019 – ident: e_1_2_11_3_1 doi: 10.1038/s41574-019-0242-2 – ident: e_1_2_11_23_1 doi: 10.2967/jnumed.116.177774 – ident: e_1_2_11_32_1 doi: 10.1152/ajpendo.00365.2002 – ident: e_1_2_11_4_1 doi: 10.1007/s00125-008-1053-5 – ident: e_1_2_11_15_1 doi: 10.1111/bcp.14591 – ident: e_1_2_11_33_1 doi: 10.1016/j.mito.2014.05.007 |
| SSID | ssj0063685 |
| Score | 2.2844992 |
| Snippet | The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized to receive... Abstract The aim of the study was to investigate if there is a clinically relevant drug interaction between metformin and codeine. Volunteers were randomized... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2408 |
| SubjectTerms | Adult Algorithms Analgesics, Opioid - administration & dosage Analgesics, Opioid - pharmacokinetics Antidiabetics Catheters Codeine Codeine - administration & dosage Cross-Over Studies CYP2D6 protein Cytochrome P450 Drug dosages Drug interaction Drug interactions Glucose Health care Healthy Volunteers Humans Intravenous administration Liquid chromatography Mass spectroscopy Metformin Morphine Morphine - administration & dosage Morphine - pharmacokinetics Oral administration Pharmacokinetics Pharmacy Plasma Plasma levels Urine Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NTtwwELYqDlUvqNBCU37kIg5cQmMncWxuFIEQEuUASNws27HFCsiibhaJG7wBz8iTMONkV6xKxaWnRMnYcsYz8Wd75jMhm4BSeZarIpXM87SoA0-tAn_0SllZeWPKGJtz_FscnhdHF-XFq6O-MCasowfuFPfTFpnzouKmdqIQhslgPXKaMSlcaUTAvy-MeZPJVPcPFkirHlMhS_B3QCU9pxDG8Lh2tM0A1FQzI1Ek7H8LZf4dLPkaxMZR6OAzme_hI93tmr1APvhmkXw87jfIv5DHEyhMTVPTAdZzFxlY6W3PT30FMkjLTIeB3vgW8eqgobgUG4vgzXDcUkzap5jrDuJYj7nCC-1SJu_paGxx8Wa0Q3dp_LTnhycMBKWRqvYrOT_YP9s7TPtTFlIHYKFKmQFIUZWmDiUztQoAAZRTwVRVrkDZyviSS-EVyyVAxdxmBmYsDkmtgzKYwrBE5pph478R6sGbnfPMORAKITeuYFARzyy3dV6ohGxNNK5dT0GOJ2Fc68lUBBqvY-ckZGMqetvxbrwl9Au7bSqAVNnxARiQ7g1Iv2dACVmddLru_XekYVKoADvzrEjIj-lr8DzcTjGNh77TaOZKIbtPQpY7G5m2JAfgI6WE0tWM9cw0dfZNM7iM7N5S4G406ira2b-_Xu-dncab7_9DDSvkE8dwnZhmuUrm2j9jvwZ4q7Xr0bVeAC_oKnw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIhLxT-BggziwCUQOz-2uaBSUVVIhQOttDfLduyyKiTbJovEDd6AZ-RJmPF6AysKp0Tx2LIzM8lne-YzIU8BpfKiVFUumed51QaeWwX-6JWyUnhj6hibc_iuOTiu3s7qWVpwG1JY5fqbGD_Ube9wjfwFwHQFaIYX1avFWY6nRuHuajpC4zK5gtRlaNViNk24GiRXjwmRNXg9YJPELISRPG4cnjOANmLjfxRp-y_Cmn-HTP4JZeO_aP862U4gku6utH6DXPLdTXL1MG2T3yLf30NlarqWzrGdL5GHlS4SS_UpyCA5M-0D_exHRK3zjuKCbKyCN_1ypJi6TzHjHcSxHXOKF7pKnPxKh6XFJZzhJd2lcWg_v_3AcFAaCWtvk-P9N0d7B3k6ayF3ABlEzgwAC1GbNtTMtCoAEFBOBSNEqWSwyviay8YrVkoAjKUtDMxbHFJbB2UwkeEO2er6zt8j1INPO-eZcyAUQmlcxaAhXlhu27JSGXm2fuPaJSJyPA_jk15PSKDzOionI08m0cWKfeMiodeotkkACbPjg_78RCf_07YqnG8EN61rqsYwGJNHajwmG1ebJmRkZ610nbx40L9tLiOPp2LwP9xUMZ0H3Wk0dqWQ4ycjd1c2MvWkBPgjpYTaYsN6Nrq6WdLNP0aOb9ngnjS-q2hn_x693jv6EG_u_38ED8g1juE4MY1yh2yN50v_EPDUaB9Fp_kFDO4hkg priority: 102 providerName: ProQuest |
| Title | Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross‐over study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.13107 https://www.ncbi.nlm.nih.gov/pubmed/34268884 https://www.proquest.com/docview/2599099204 https://www.proquest.com/docview/2552994949 https://pubmed.ncbi.nlm.nih.gov/PMC8604249 https://doaj.org/article/b40ce672adc646a18fbe9434186c5a6f |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VVkJcEG8CZWUQBy5BifOwDae2alUhtVTQSnuLbMeGVSFbNVkkbvAP-I38Emach7qiSFx2o2Rs2Rl_yWd75gvAS2SpPMlUHsvU8TivPY-NQjw6pYwUTusixOYcHZeHZ_m7eTHfgLdjLkyvDzEtuBEywvOaAK5NewXktmtfp0hOxA3YotRaiufj-cn4GC5JWT1kQxYIeSQmg6wQhfFMRddeRkGz_zqi-Xe85FUeG15EB3fg9sAg2U7v8ruw4Zp7cPNo2CO_Dz_fY2Gmm5otqJ5vQYSVXQwS1edoQ8rMbOnZV9cRZV00jFZjQxE6WK46Rnn7jNLd0Zzq0ef0x_qsye-sXRlav2nfsB0Wuvb7xy-KBWVBrfYBnB3sn-4dxsOHFmKLfEHEqUZWIQpd-yLVtfLIApRVXguRKemN0q7gsnQqzSSyxcwkGictlnStvdKUxfAQNptl4x4Dcwhoa11qLRp5n2mbp1gRTww3dZarCF6Nd7yygwo5fQzjSzXORrDxVXBOBC8m04teeuM6o11y22RAatnhxPLyUzWArzJ5Yl0puK5tmZc6xT450sVLZWkLXfoItkenVwOE2wrnhQrpM0_yCJ5PlxF8tKOiG4e-q2ikK0UCPxE86sfI1JIMuY-UEkuLtdGz1tT1K83icxD4liVtSNO9CuPs372v9k4_hoMn_2_6FG5xissJ-ZTbsNldrtwzJFadmQUA4a-Yixls7e4fn3yYhUWKP3pwJRI |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKkYAL4p9AAYNA4hJInD8bCaFSqLa0Ww5spb0Zx7HbVSFZmiyoN3gDnoSH4kmYcX5gReHW00absWVnZjyf7fFnQh4CSmVBJGKfh4b5cWGZnwvwRyNEzjOjVOJyc8a76WgvfjNNpivkR38WBtMq-zHRDdRFpXGN_CnAdAFohgXxi_knH2-Nwt3V_gqN1iy2zfEXmLLVz7degX4fMbb5erIx8rtbBXwNwTHzQwUhNEtUYZNQFcJCyBNaWJVlkeA2F8okjKdGhBEHaBTlgQKErpHE2QqFKftQ7xlyFgJvgJO9bDpM8FIkc3cHMBMYZQALdUxGmDmkm_pJiEWW4p-7JuAkbPt3iuaf0NnFvs1L5GIHWul6a2WXyYopr5Bz425b_ir59hYKU1UWdIb1fHa8r3TesWIfggySQdPK0o-mQZQ8KykuALsi-FAtGopUARRP2IM41qMO8Ye2BzWPab3IccmofkbXqevaz6_fMf2UOoLca2TvVLRwnayWVWluEmpgDNHahFqDkLWR0nEIFbEgZ3kRxcIjj_svLnVHfI73b3yQ_QQIGi-dcjzyYBCdt2wfJwm9RLUNAkjQ7f6ojvZl5-8yjwNt0oypQqdxqkLok0EqvpCnOlGp9char3TZjRq1_G3jHrk_vAZ_x00cVRrQnUTnEgI5hTxyo7WRoSURwC3OOZTOlqxnqanLb8rZgeMU5ynugeO3cnb2797Ljck793Dr_z24R86PJuMdubO1u32bXGCYCuSOcK6R1eZoYe4Almvyu86BKHl_2h77CwVQXHk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VrVRxQfwTKGAQSFxCE-fXSAj1b9VSulTQSr2ljmPDqpAsTRbUG7wBz8Pj8CTMOMnCisKtp402Y8vOzHg-2-PPAI8QpXIvEKGb-pq7YWG4mwv0Ry1EniZaysjm5uyO4q2D8OVhdLgAP_qzMJRW2Y-JdqAuKkVr5CsI0wWiGe6FK6ZLi9jbGL6YfHLpBinaae2v02hNZEeffsHpW_18ewN1_Zjz4eb--pbb3TDgKgyUietLDKdJJAsT-bIQBsOfUMLIJAlEanIhdcTTWAs_SBEmBbknEa0rInQ2QlL6PtZ7ARYTmhUNYHFtc7T3po8DMVG72-OYEY45iIw6XiPKI1JN_dRHYJXMRUN7acBZSPfvhM0_gbSNhMPLcKmDsGy1tbkrsKDLq7C0223SX4Nvr7Ewk2XBxlTPZ8sCyyYdR_YxyhA1NKsM-6gbwszjktFysC1CD9W0YUQcwOi8PYpTPfKYflh7bPOU1dOcFpDqZ2yV2a79_PqdklGZpcu9DgfnoocbMCirUt8CpnFEUUr7SqGQMYFUoY8VcS_neRGEwoEn_RfPVEeDTrdxfMj66RA2PrPKceDhTHTScn-cJbRGapsJEF23_aM6eZd13p_load0nHBZqDiMpY990kTM56eximRsHFjulZ51Y0id_bZ4Bx7MXqP305aOLDXqLiNXE4IYhhy42drIrCUBgq80TbF0Mmc9c02df1OO31uG8TSmHXH6VtbO_t37bH3_rX24_f8e3Icl9Nbs1fZo5w5c5JQXZM9zLsOgOZnquwjsmvxe50EMjs7baX8BJXliFA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+and+intravenous+pharmacokinetics+of+metformin+with+and+without+oral+codeine+intake+in+healthy+subjects%3A+A+cross%E2%80%90over+study&rft.jtitle=Clinical+and+translational+science&rft.au=Kuhlmann%2C+Ida&rft.au=N%C3%B8ddebo+Nyrup%2C+Amanda&rft.au=Bjerregaard+Stage%2C+Tore&rft.au=Hougaard+Christensen%2C+Mette+Marie&rft.date=2021-11-01&rft.issn=1752-8054&rft.eissn=1752-8062&rft.volume=14&rft.issue=6&rft.spage=2408&rft.epage=2419&rft_id=info:doi/10.1111%2Fcts.13107&rft.externalDBID=10.1111%252Fcts.13107&rft.externalDocID=CTS13107 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-8054&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-8054&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-8054&client=summon |